Monthly Prescribing Reference

Simponi Aria Approved for Polyarticular JIA, Pediatric Psoriatic Arthritis

Simponi Aria is available as a 50mg/4mL strength solution for IV infusion; it is administered as a 30-minute infusion. The Food and Drug Administration (FDA) has approved Simponi Aria® (golimumab; ...
Business Wire

Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE® and SIMPONI®

WHITEHOUSE STATION, N.J. & NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson & Johnson (NYSE: JNJ) and its subsidiary Centocor ...
Business Insider

SIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic ...

HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...
Reuters

Big-profile Schering arthritis drug wins Canada nod

NEW YORK, April 13 (Reuters) - Johnson & Johnson and Schering-Plough Corp said on Monday that Canadian regulators had approved use of their experimental once-monthly drug Simponi to treat moderate to ...